



IQWiG Reports – Commission No. E18-05

**Amyloid PET in dementia of
unclear aetiology**
Addendum to Commission E18-03¹

Extract

¹ Translation of the executive summary of the addendum *Amyloid-PET bei Demenz unklarer Ätiologie – Addendum zum Auftrag E18-03* (Version 1.0; Status: 19 July 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.

Publishing details

Publisher:

Institute for Quality and Efficiency in Health Care

Topic:

Amyloid PET in dementia of unclear aetiology – Addendum to Commission E18-03

Commissioning agency:

Federal Joint Committee

Commission awarded on:

1 June 2018

Internal Commission No.:

E18-05

Address of publisher:

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Im Mediapark 8
50670 Köln
Germany

Phone: +49 221 35685-0

Fax: +49 221 35685-1

E-mail: berichte@iqwig.de

Internet: www.iqwig.de

IQWiG employees involved in the assessment of potential:

- Britta Runkel
- Charlotte Guddat
- Julia Kreis
- Dorothea Sow

Keywords: Positron-Emission Tomography, Alzheimer Disease, Assessment of Potential, Systematic Review

Executive summary

With its letter of 1 June 2018, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) with a supplementary assessment of commission E18-03 in order to evaluate the conclusions on the potential (in terms of §137e Social Code Book V) of the amyloid positron emission tomography (amyloid PET) method in dementia of unclear aetiology.

Research question

The aim of this investigation was to determine for amyloid PET in dementia of unclear aetiology whether, besides the documents already used in the assessment of potential E18-03, further relevant studies or documents on relevant studies exist. If this was the case, it was to be evaluated whether, under their consideration, the present examination or treatment method still offers potential. Furthermore, it was to be evaluated whether, besides the studies already considered in the assessment of potential, there are any ongoing studies that in principle are suited to provide relevant information on the benefit of the method in the near future.

Methods

Randomized controlled trials (RCTs) or documents on RCTs were included that investigated amyloid PET method in dementia of unclear aetiology and that had not already been used within the framework of the assessment of potential.

A systematic literature search for primary studies was performed in the databases MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. In parallel, a search for relevant systematic reviews was performed in the databases MEDLINE, Embase, the Cochrane Database of Systematic Reviews, and the Health Technology Assessment (HTA) Database. The search was conducted on 6 June 2018. In addition, systematic reviews and study registries were searched. The selection of relevant studies was performed by 2 reviewers independently of each other.

The assessment, synthesis and analysis of information followed the principles described in the Institute's general methods paper.

Results

No additional relevant completed or ongoing studies were identified by the information retrieval.

Two additionally identified documents on the completed Pontecorvo 2017 study, which had already been considered in the assessment of potential, did not lead to a change in the evaluation regarding the potential. There was also no new information on a currently planned study that had already been considered in the assessment of potential.

Conclusion

After a systematic evaluation, amyloid PET in dementia of unclear aetiology still possesses a potential. Beyond those studies already considered in the assessment of potential, no further completed or ongoing studies were found that in principle would be suited to demonstrate a benefit of the method in the near future.

The full report (German version) is published under <https://www.iqwig.de/en/projects-results/projects/non-drug-interventions/e18-05-amyloid-pet-in-dementia-of-unclear-aetiology-addendum-to-commission-e18-03.13081.html>.